A review of ceftriaxone: a long-acting cephalosporin.
Vanderbilt University Medical Center, Nashville, Tennessee.The American Journal of the Medical Sciences (Impact Factor: 1.39). 10/1988; 296(3):221-2.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
Article: Ceftaroline[Show abstract] [Hide abstract]
ABSTRACT: Cephalosporins are widely used antibiotics throughout the world. However, with the availability of multiple agents in this class with varying spectrum of activity and clinical use, selecting the most appropriate cephalosporin can become convoluted. Ceftaroline, a new-generation cephalosporin recently approved in the United States for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection may further complicate this dilemma. Ceftaroline is easily distinguishable compared to the other intravenous cephalosporins given its activity against methicillin-resistant Staphylococcus aureus (MRSA) including multidrug-resistant MRSA. Unfortunately, its Food and Drug Administration–approved indications offer little benefit for the antimicrobial, given cheaper, oral, and more experienced antimicrobials for these indications exist. Ceftaroline may be more appealing in the treatment of infections that require broad-spectrum intravenous antibiotics empirically (eg, endocarditis, meningitis, and osteomyelitis), especially if MRSA is a concern. However, future studies are needed to evaluate its efficacy for these indications. Until these are completed, ceftaroline should be considered as an alternative for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection at this time.Infectious Disease in Clinical Practice 01/2014; 22(1):8-17. DOI:10.1097/IPC.0b013e3182948d1c